Pennsylvania Awards $10 Million to 23 Entities

Governor Tom Wolf announced that 23 awardees will receive $10 million in grant funding through the COVID-19 Vaccines, Treatments and Therapies (CV-VTT) program to support the rapid advancement of vaccines, treatments and therapies by qualified biotechnology entities in response to the COVID-19 pandemic.

Evrys Bio was awarded over $300,000 to develop treatments for virus caused respiratory infections.  To date, Evrys Bio has seen excellent activity of certain proprietary pre-clinical leads against both corona viruses and influenza viruses.

Press Release

Evrys Bio awarded a supplement to its NIH National Institute for Allergy and Infectious Disease titled, “A Single Antiviral to Treat Multiple Opportunistic Infections”

July 22, 2020:  In response to emergency research funding for COVID-19, the supplement extends testing of Evrys broad-spectrum antivirals to coronaviruses including SRAS-CoV-2. ABSTRACT

November 21, 2019 – Evrys Bio President & CEO, Lillian Chiang gives oral presentation, “Host Sirtuin-2 Protein (SIRT2) – A Validated Target for Broadly-Effective Antiviral Small-Molecule Drugs”

November 21, 2019 – Evrys Bio President & CEO, Lillian Chiang gives oral presentation, “Host Sirtuin-2 Protein (SIRT2) – A Validated Target for Broadly-Effective Antiviral Small-Molecule Drugs,” at the 2019 Chemical and Biological Defense Science & Technology (CBD S&T) Conference Cincinnati, OH.   See the PowerPoint Presentation

July 31, 2019 – Evrys Bio awarded Phase II SBIR grant from the NIH National Institute for Allergy and Infectious Disease

Evrys Bio awarded Phase II SBIR grant from the NIH National Institute for Allergy and Infectious Disease titled, “A Single Antiviral to Treat Multiple Opportunistic Infections” (5R44AI11407902).  Details are HERE